Rapporter | 2 Nov 2022 | Enzymatica

Enzymatica AB: Interim report Q3/2022: A broader role for ColdZyme adds potential for the future

  

Significant Significant events after the quarter
events during
the quarter

• To ensure · On October 31, the journal Respiratory Research published a

the long-term study from the Medical University of Innsbruck, Austria, which
financing of shows that ColdZyme blocks the widespread and highly
the business, transmissible omicron variants BA.4 and BA.5 from adhering to
in September and infecting human cells. According to the research group that
the company conducted the study, this opens the possibility that ColdZyme
raised about can be applied in the prevention of SARS-CoV-2 spreading.
SEK 74.7 Continued clinical trials are needed to establish the effect in
million vivo.
before issue
expenses
through a
rights issue.
The rights
issue was
fully
subscribed,
including 63
percent
subscribed
with the
support of
subscription
rights and 1
percent
without the
support of
subscription
rights. The
company’s
three largest
shareholders,
along with
the CEO and
the Chairman
of the Board,
subscribed
for the
remainder, 36
percent, in
accordance
with the
guarantee
commitments.

Other events
during the
quarter

• The

company’s mouth
spray was
launched in
Mexico and
Turkey,
expanding the
company’s
market by more
than 200
million
consumers.

Third quarter January-September

• Net sales · Net sales reached SEK 32.3

reached SEK (38.5) million.
18.5 (15.4) · The operating result totaled SEK
million. -46.6 (-34.7) million.

• The · Earnings per share, basic and

operating diluted, were SEK -0.31 (-0.24).
result · Cash flow from operating
totaled SEK activities totaled SEK 37.7 (-29.3)
-12.6 (-6.0) million.
million. · Net cash totaled SEK 57.3 (35.7)

• The million.

operating
result
includes non
-recurring
costs of SEK
6.2 million
as an effect
of
renegotiation
of agreements
with two of
the company’s
business
partners.

• Earnings

per share,
basic and
diluted, were
SEK -0.08 (
-0.04).

• Cash flow

from
operating
activities
totaled SEK
-6.0 (-16.2)
million.

• Cash flow

from
financing
activities
totaled SEK
81.1 million,
of which SEK
69.1 refer to
rights issue
carried out
in September.

”The study that has been published in Respiratory Research shows ColdZyme has the potential to move from a cold remedy product to a complement to vaccines in the protection against Covid-19. After a couple of very hard years, many signs now indicate that Enzymatica has passed the austerity caused by the pandemic. We see good possibilities of expanding in new and existing markets, we have a good organization in place, and strong business partners. I am convinced that there are a number of exciting and successful years ahead of us”, said Claus Egstrand, CEO of Enzymatica.

The full year-end report is available on: www.enzymatica.com/investors/financial-reports

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET
on 2 November 2022.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica’s Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: certifiedadviser@penser.se